Previous close | 155.10 |
Open | 154.85 |
Bid | 154.95 x 0 |
Ask | 155.40 x 0 |
Day's range | 154.10 - 155.80 |
52-week range | 125.55 - 222.00 |
Volume | |
Avg. volume | 533,454 |
Market cap | 12.077B |
Beta (5Y monthly) | 1.34 |
PE ratio (TTM) | 8.07 |
EPS (TTM) | 19.20 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 277.00 |
COPENHAGEN, Denmark, March 21, 2024 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Tuesday, 16 April 2024, at 4 PM CEST at Comwell Borupgaard, Nørrevej 80, DK-3070 Snekkersten, Denmark with the following agenda: The Board of Directors' report on the Company's activities in the past year.Presentation of the Annual Report for adoption.A proposal from the Board of Directors regardin
COPENHAGEN, Denmark, March 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Swiss Agency for Therapeutic Products, Swissmedic, has approved JYNNEOS® (MVA-BN) for active immunization against disease caused by smallpox, mpox and vaccinia viruses in adults 18 years of age and older. The approval represents the first national marketing authorization issued to Bavarian Nordic since 2019 and was facilitated by the Swiss authorities in response to the 2022 global mpox outbreak. Durin
COPENHAGEN, Denmark, March 12, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523. The transactions concern the vesting of restricted stock units (RSUs) including matc